
Molecular Pathway Analysis Using High-Throughput OMICS Molecular Data
Analysis of molecular pathway composition, architecture, and activation using high-throughput genomic, epigenetic, transcriptomic, proteomic, and metabolomic data
- 1st Edition - October 26, 2024
- Imprint: Academic Press
- Editor: Anton Buzdin
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 5 5 6 8 - 0
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 5 5 6 9 - 7
The field molecular pathway analysis evolves rapidly, and many progressive methods have recently been discovered. Molecular Pathway Analysis Using High-Throughput OMICS Data conta… Read more

Purchase options

Institutional subscription on ScienceDirect
Request a sales quoteThe field molecular pathway analysis evolves rapidly, and many progressive methods have recently been discovered. Molecular Pathway Analysis Using High-Throughput OMICS Data contains the largest collections of molecular pathways. For the first time, guidelines on how to do genomic, epigenetic, transcriptomic, proteomic, and metabolomic data analysis in real-world research practice are given. Molecular Pathway Analysis Using High-Throughput OMICS Molecular Data also focuses on the pathway analysis applications for solving tasks in biotechnology, pharmaceutics, and molecular diagnostics It demonstrates how pathway analysis can be applied for the research and treatment of chronic and acute diseases, for next-generation molecular diagnostics, for drug design and preclinical testing; relevant real-world examples, molecular tests, and web resources will be reviewed in-depth. The book shows a tendency of erasing the borders between chemistry, physics, informatics, mathematics, biology, and medicine by means of novel research approaches and instruments, providing a truly multidisciplinary approach.
- Provides theoretical insights, links to available resources and their descriptions, and protocols related to multiple possibilities and options of the molecular pathway analysis
- Elucidates unique instruments (i) for the quantitative pathway analysis using metabolomic data, and (ii) for algorithmic hypothesis-free reconstruction and functional annotation of the molecular pathways that have a strong potential to revolutionize the field
- Includes intuitive practical guidelines on the analysis of genomic, epigenetic, transcriptomic, proteomic, and metabolomic data at the molecular pathway level for non-bioinformaticians
- Provides state-of-the art in the field of Big molecular data analysis for research, medicine, biotechnology, pharmaceutics, and next-generation molecular diagnostics
- Title of Book
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- About the editor
- Preface
- Part I. Foundational information
- Chapter 1. Past, current, and future of molecular pathway analysis
- 1.1 Molecular pathways
- 1.2 Quantitative omics data
- 1.3 Different levels of omics data analysis
- 1.4 Quantization of IMP activities
- 1.4.1 Annotation of functional roles for pathway participants
- 1.5 Applications of IMP analysis
- 1.5.1 Applications in medicine
- 1.6 Software for quantitative assessment of IMP activation
- 1.7 Concluding remarks
- Chapter 2. Molecular data for the pathway analysis
- 2.1 Omics data available for the molecular pathway analysis
- 2.2 Data needed to reconstruct IMPs
- 2.3 Data needed to estimate activation levels of IMPs
- Chapter 3. Benefits and challenges of OMICS data integration at the pathway level
- 3.1 Background
- 3.2 The comparison
- 3.2.1 Functional annotation of gene expression data
- 3.2.1.1 Topology analysis of pathway phenotype association
- 3.2.1.2 Topology-based score
- 3.2.1.3 Pathway-Express
- 3.2.1.4 Signal pathway impact analysis
- 3.2.2 Statistical tests
- 3.2.3 Mathematical modeling
- 3.2.4 Analysis of gene expression datasets
- 3.2.5 Biological relevance of cross-platform harmonized expression data
- 3.2.5.1 PTSD gene expression datasets
- 3.2.6 Marker gene and pathway analysis
- 3.3 Results
- 3.3.1 Cross-platform processing of transcriptomic and proteomic data
- 3.3.2 Building pathway activation profiles and assessment of batch effects
- 3.3.3 Mathematical modeling of data aggregation effects
- 3.3.4 Experimental model of cross-platform comparisons
- 3.3.5 Data aggregation effects assessed for RNA and protein expression levels
- 3.3.6 Comparison of data aggregation capacities of different PAL scoring methods
- 3.3.7 Retention of biological features
- 3.3.8 Gene and pathway analysis of PTSD datasets
- 3.4 Discussion
- Abbreviations
- Chapter 4. Controls for the molecular data: Normalization, harmonization, and quality thresholds
- 4.1 Background
- 4.2 Principles of harmonization algorithms
- 4.3 Differential clustering of human normal and cancer expression profiles
- 4.4 Correlation, regression, and sign-change analysis of cancer drug balanced efficiency score (BES) after application of different methods of harmonization
- 4.5 Discussion
- Abbreviations
- Chapter 5. Reconstruction of molecular pathways
- 5.1 Molecular pathways
- 5.2 An approach to reconstruct the pathway
- 5.2.1 The interactome model
- 5.2.2 Building gene-centric pathways
- 5.2.3 Overall functional annotation of reconstructed pathways—gene ontology classification
- 5.2.4 Visual annotation of reconstructed pathways
- 5.2.5 Algorithmic annotation of functional roles for pathway components
- 5.2.6 Examples of building and annotation of molecular pathways
- Chapter 6. Qualitative and quantitative molecular pathway analysis: Mathematical methods and algorithms
- 6.1 Background
- 6.2 Topology-based methods for pathway activation assessment
- 6.2.1 Oncobox
- 6.2.2 Topology analysis of pathway phenotype association
- 6.2.3 Topology-based score
- 6.2.4 Pathway-express
- 6.2.5 Signal pathway impact analysis
- 6.2.6 iPANDA (in silico pathway activation network decomposition analysis)
- 6.3 Methods for database preparation for pathway activation assessment
- 6.3.1 Curation of pathway databases
- 6.3.2 Algorithmic annotation of pathway graph nodes
- 6.3.3 Finding gene importance factors for iPANDA
- 6.4 Personalized ranking of cancer drugs based on PALs
- 6.4.1 Oncobox balance efficiency score (BES)
- 6.4.2 Drug efficiency index (DEI)
- 6.5 Multi-omics data pathway analysis
- 6.5.1 Pathway activation assessment for methylome, microRNAs, and long noncoding (LNC) antisense (AS) RNAs
- 6.6 Concluding remarks
- Abbreviations
- Part II. Methods and guidelines
- Chapter 7. Getting started with the molecular pathway analysis
- 7.1 Strategies of pathway analysis
- 7.2 Reconstruction of pathways and networks
- 7.3 The devil is in the things
- 7.4 Applications of molecular pathway analysis
- 7.5 Preprocessing of data for pathway analysis
- 7.6 Visualization of pathways
- Chapter 8. Molecular pathway analysis using comparative genomic and epigenomic data
- 8.1 Types of pathway analysis requiring (epi)genomic data
- 8.2 Profiling of genomic pathway instability by using DNA mutation data
- 8.2.1 Initial mutation data
- 8.2.2 Algorithm validation dataset
- 8.2.3 Molecular target interrogation dataset
- 8.2.4 Clinical trial data
- 8.2.5 Molecular pathway data
- 8.2.6 Pathway instability scoring
- 8.2.7 PI analysis of cancer mutation signatures
- 8.2.8 PI-based drug scoring
- 8.2.9 Assessment of MDS family methods performance using clinical trial data
- 8.2.10 Application of MDS to identify putative drug target genes
- 8.3 Epigenetic marks as the measure of IMP molecular evolution
- 8.3.1 Study design
- 8.3.2 Source IMPs
- 8.3.3 Aggregated dN/dS data
- 8.3.4 RE regulation enrichment data
- 8.3.5 Functional classification of histone modifications
- 8.3.6 Aggregated NGRE score
- 8.3.7 Correlation between structural and regulatory evolutionary rate metrics
- 8.3.8 Functional groups of genes and pathways with different evolutionary rates
- 8.4 Concluding remarks
- Chapter 9. Quantitative molecular pathway analysis using transcriptomic and proteomic data
- 9.1 Types of molecular pathway analysis
- 9.2 Quantitative analysis of gene expression
- 9.3 Quantitative assessment of the pathway activities
- 9.3.1 Calculation of PAL
- 9.3.2 Annotation of functional roles of IMP members
- 9.4 Software
- 9.4.1 Visualization of the pathways
- 9.4.2 Manual on the installation of oncoboxlib library
- Chapter 10. MicroRNA data for quantitative analysis of molecular pathways
- 10.1 Relevance of microRNA profiles to molecular pathway activation analysis
- 10.2 Algorithmic analysis of pathway activation
- 10.3 Applications of pathway analysis for microRNAs
- 10.3.1 MiRImpact application to profile regulation of IMPs in bladder cancer
- 10.3.2 MiRImpact application to profile regulation of IMPs during cytomegaloviral infection
- 10.4 Concluding remarks
- Chapter 11. Methods and tools for OMICS data integration
- 11.1 A snapshot of the current state of OMICS integration landscape
- 11.2 The most important part of this chapter
- 11.3 Best practices in preprocessing multiomics datasets
- 11.4 OMICS data integration in the eyes of a life scientist
- 11.4.1 From genotype to phenotype: Step I—Transcription
- 11.4.1.1 Unraveling gene regulatory networks (GRNs)
- 11.4.1.2 Decoding alternative splicing
- 11.4.1.3 Spotting novel transcripts
- 11.4.1.4 Quantifying gene expression
- 11.4.1.5 Probing post-transcriptional regulation
- 11.4.1.6 Integrating genomic variants and gene expression
- 11.4.1.7 Noncoding RNAs disrobed
- 11.4.2 From genotype to phenotype: Step II—Translation
- 11.4.3 From genotype to phenotype: Step III—Proteins
- 11.4.4 From genotype to phenotype: Step IV—Metabolites
- 11.5 Data scientist summary
- 11.6 Life scientist summary
- Part III. Practical applications
- Chapter 12. Molecular pathway approach in clinical oncology
- 12.1 Gene expression data in clinical oncology
- 12.2 Conversion of pathway activation data into personalized prediction of cancer drug efficacy
- 12.2.1 Molecular pathway databank
- 12.2.2 Clinical trial database
- 12.2.3 Drug target database
- 12.2.4 Algorithmic scoring of cancer drug efficiencies
- 12.3 Examples of IMP-based clinical ranking of drugs in oncology
- 12.3.1 Example 1. Ranking of cancer drugs based on mRNA expression data
- 12.3.2 Example 2. Comparison of alternative drug scoring methods
- 12.4 Conclusion
- Chapter 13. Molecular pathway approach in pharmaceutics
- 13.1 Molecular pathway analysis in general
- 13.1.1 What is intracellular molecular pathway
- 13.1.2 Molecular pathway analysis
- 13.1.3 Pathway analysis instruments
- 13.2 Pathway analysis to facilitate tasks in molecular pharmacology
- 13.2.1 Task 1. To establish mechanism of action of drug candidate X
- 13.2.2 Task 2. To identify robust response biomarkers for drug (candidate) X
- 13.2.3 Task 3. To identify drugs that act similarly to drug (candidate) X or to identify molecular targets of X
- 13.3 Practical examples how IMP analysis may help
- 13.4 Useful online resources
- 13.5 Conclusion
- Chapter 14. Molecular pathway approach in biotechnology
- 14.1 Pathways of biotechnology
- 14.1.1 Biotechnology
- 14.1.2 The pathways
- 14.1.3 Molecular pathways in biotech
- 14.2 Examples of pathway analysis in biotechnology
- 14.2.1 Golden rice
- 14.2.2 A humanized N-glycosylation system for expression of human proteins in yeast
- 14.2.3 Optimization of the photosynthesis system
- 14.3 Conclusion and perspective
- Chapter 15. Molecular pathway approach in biology and fundamental medicine
- 15.1 Molecular pathway analysis in biomedicine
- 15.2 IMP analysis in oncology
- 15.2.1 IMPs in cancer
- 15.2.2 Quantitative analysis of IMPs in oncology
- 15.2.3 IMPs as cancer biomarkers
- 15.2.4 Pathway-based scoring of cancer drug efficiencies
- 15.2.4.1 Gene signature PAL biomarkers
- 15.2.4.2 Molecular mechanism-based biomarkers
- 15.2.4.3 Translation to personalized medicine
- 15.3 Other applications of IMP analysis in biomedicine
- 15.3.1 Ranking and repurposing of drugs
- 15.3.2 Understanding molecular mechanisms
- 15.4 Conclusion
- Index
- Edition: 1
- Published: October 26, 2024
- Imprint: Academic Press
- No. of pages: 408
- Language: English
- Paperback ISBN: 9780443155680
- eBook ISBN: 9780443155697
AB